Research Advances and Treatment of Risk Factors for Postoperative Urosepsis Following Percutaneous Nephrolithotomy

Bobo Tang; Lei Si; Junfu Du; Yong Zhang; Dengliang Cheng

doi:10.54097/1yzafx31

Authors

Bobo Tang
Lei Si
Junfu Du
Yong Zhang
Dengliang Cheng

DOI:

https://doi.org/10.54097/1yzafx31

Keywords:

Percutaneous Nephrolithotomy (PCNL), Urosepsis, Risk Factors, Treatment

Abstract

Percutaneous Nephrolithotomy (PCNL) is the preferred treatment for complex upper urinary tract stones and large-burden (diameter >2 cm) or multiple renal calculi, offering advantages such as higher efficacy, minimal invasiveness, and faster recovery compared to traditional surgery. However, it carries a significant risk of urosepsis. Currently, the incidence of urosepsis associated with urinary stones has not declined despite advances in diagnostic and therapeutic techniques, remaining one of the most critical complications in urology. Its high mortality rate poses significant challenges to clinicians. This article reviews the potential risk factors and therapeutic approaches for post-PCNL urosepsis.

Downloads

Download data is not yet available.

References

[1] Zeng G H, Mai Z L, Xia S J, et al. Cross-sectional survey on the prevalence of urolithiasis in Chinese adult population[J]. Chinese Journal of Urology, 2015(7):528-532.

[2] Huang J, Zhang X. Guidelines for Diagnosis and Treatment of Urological and Andrological Diseases in China: 2022 Edition[M]. Beijing: Science Press, 2022:389.

[3] G. Bonkat (Chair), R.B. (Vice-chair), F. Bruyère, et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan Italy 2021[J]. 2021. (G. Bonkat Chair R B F B, Guidelines Associates W. Devlies J H G M. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan Italy 2021[J]. 2021.)

[4] Zeng G H, Mai Z L, Yuan J, et al. MPCNL for upper urinary tract calculi: a single-center report of 10452 cases over 19 years[J]. Chinese Journal of Urology, 2012(10):767-770.

[5] Abdelhafez M F, Bedke J, Amend B, et al. Minimally invasive percutaneous nephrolitholapaxy (PCNL) as an effective and safe procedure for large renal stones[J]. BJU Int, 2012,110(11 Pt C): E1022-E1026.

[6] Whitehurst L, Jones P, Somani B K. Mortality from kidney stone disease (KSD) as reported in the literature over the last two decades: a systematic review[J]. World Journal of Urology, 2019,37(5):759-776.

[7] Yu J, Guo B, Yu J, et al. Antibiotic prophylaxis in perioperative period of percutaneous nephrolithotomy: a systematic review and meta-analysis of comparative studies[J]. World Journal of Urology, 2020,38(7):1685-1700.

[8] Levy M M, Artigas A, Phillips G S, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study[J]. Lancet Infect Dis, 2012,12(12):919-924.

[9] Martín S, Pérez A, Aldecoa C. Sepsis and Immunosenescence in the Elderly Patient: A Review[J]. Frontiers in Medicine, 2017,4.

[10] Rhodes A, Evans L E, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Critical care medicine, 2017,45(3):486-552.

[11] Sun J, Xu J, OuYang J. Risk Factors of Infectious Complications following Ureteroscopy: A Systematic Review and Meta-Analysis[J]. Urologia Internationalis, 2020,104(1-2):113-124.

[12] Chugh S, Pietropaolo A, Montanari E, et al. Predictors of Urinary Infections and Urosepsis After Ureteroscopy for Stone Disease: a Systematic Review from EAU Section of Urolithiasis (EULIS)[J]. Current Urology Reports, 2020,21(4).

[13] Baboudjian M, Gondran-Tellier B, Abdallah R, et al. Predictive risk factors of urinary tract infection following flexible ureteroscopy despite preoperative precautions to avoid infectious complications[J]. World Journal of Urology, 2020,38(5):1253-1259.

[14] Du J H, Xiang Q, Yang Z Q, et al. Analysis of influencing factors of urosepsis in patients after percutaneous nephrolithotomy[J]. International Journal of Urology and Nephrology, 2021(01):49-52.

[15] Khusid J A, Hordines J C, Sadiq A S, et al. Prevention and Management of Infectious Complications of Retrograde Intrarenal Surgery[J]. Frontiers in surgery, 2021,8:718583.

[16] Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women[J]. Climacteric, 2019,22(3):242-249.

[17] Bowling M R, Xing D, Kapadia A, et al. Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors[J]. Arterioscler Thromb Vasc Biol, 2014,34(7):1477-1485.

[18] Zhu Z J, Xu Q Q, Huang X B, et al. Analysis of risk factors for systemic inflammatory response syndrome after percutaneous nephrolithotomy in diabetic patients[J]. Journal of Peking University (Health Sciences), 2016,48(04):643-649.

[19] Confederat L G, Condurache M I, Alexa R E, et al. Particularities of Urinary Tract Infections in Diabetic Patients: A Concise Review[J]. Medicina (Kaunas), 2023,59(10).

[20] Trevelin S C, Carlos D, Beretta M, et al. Diabetes Mellitus and Sepsis: A Challenging Association[J]. Shock, 2017,47(3):276-287.

[21] Liu Y Q, Lu J, Hao Y C, et al. Related risk factors and prediction model of urosepsis after percutaneous nephrolithotomy[J]. Journal of Peking University (Health Sciences), 2018,50(03):507-513.

[22] Hao X, Wang X, Wei H, et al. Development and Validation of the Prediction Model of Sepsis in Patients After Percutaneous Nephrolithotomy and Sepsis Progresses to Septic Shock[J]. J Endourol, 2023,37(4):377-386.

[23] Aljuhayman A, Abunohaiah I, Addar A, et al. Assessment of lower calyceal single-access percutaneous nephrolithotomy for staghorn stones: A single-surgeon and a single-center experience at KAMC, Riyadh[J]. Urol Ann, 2019,11(1):62-65.

[24] El-Nahas A R, Nabeeh M A, Laymon M, et al. Preoperative risk factors for complications of percutaneous nephrolithotomy[J]. Urolithiasis, 2021,49(2):153-160.

[25] Zhou G, Zhou Y, Chen R, et al. The influencing factors of infectious complications after percutaneous nephrolithotomy: a systematic review and meta-analysis[J]. Urolithiasis, 2022,51 (1):17.

[26] Scotland K B, Lange D. Prevention and management of urosepsis triggered by ureteroscopy[J]. Research and reports in urology, 2018,10:43-49.

[27] Goto T, Nakame Y, Nishida M, et al. Bacterial biofilms and catheters in experimental urinary tract infection[J]. Int J Antimicrob Agents, 1999,11(3-4):227-231, 237-239.

[28] Zumstein V, Betschart P, Albrich W C, et al. Biofilm formation on ureteral stents - Incidence, clinical impact, and prevention[J]. Swiss Med Wkly, 2017,147: w14408.

[29] Kehinde E O, Rotimi V O, Al-Awadi K A, et al. Factors predisposing to urinary tract infection after J ureteral stent insertion[J]. Journal of Urology, 2002,167(3):1334-1337.

[30] Werneburg G T, Hettel D, Lundy S D, et al. Ureteral Stents Harbor Complex Biofilms With Rich Microbiome-Metabolite Interactions[J]. Journal of Urology, 2023,209(5):950-962.

[31] Venkatesh R, Landman J, Minor S D, et al. Impact of a Double-Pigtail Stent on Ureteral Peristalsis in the Porcine Model: Initial Studies Using a Novel Implantable Magnetic Sensor[J]. Journal of Endourology, 2005,19(2):170-176.

[32] Liu J, Zhou C, Gao W, et al. Does preoperative urine culture still play a role in predicting post-PCNL SIRS? A retrospective cohort study[J]. Urolithiasis, 2020,48(3):251-256.

[33] Ahmed A E, Abol-Enein H, Awadalla A, et al. Investigation of Virulence Genes of the Predominant Bacteria Associated with Renal Stones and their Correlation with Postoperative Septic Complications[J]. Infect Drug Resist, 2022,15:3643-3655.

[34] Korets R, Graversen J A, Kates M, et al. Post-percutaneous nephrolithotomy systemic inflammatory response: a prospective analysis of preoperative urine, renal pelvic urine and stone cultures[J]. J Urol, 2011,186(5):1899-1903.

[35] Lin W J, Luo Y B, Long Y F, et al. Analysis of risk factors and predictive indicators of infectious complications after percutaneous nephrolithotomy for complex renal calculi[J]. International Journal of Urology and Nephrology, 2020 (06): 1027-1030.

[36] Du C, Song L, Wu X, et al. Suctioning Minimally Invasive Percutaneous Nephrolithotomy with a Patented System Is Effective to Treat Renal Staghorn Calculi: A Prospective Multicenter Study[J]. Urologia Internationalis, 2018,101(2): 143-149.

[37] Zeng G, Zhang T, Agrawal M, et al. Super-mini percutaneous nephrolithotomy (SMP) vs retrograde intrarenal surgery for the treatment of 1-2 cm lower-pole renal calculi: an international multicentre randomised controlled trial[J]. BJU Int, 2018,122 (6):1034-1040.

[38] Du C, Song L, Wu X, et al. Suctioning Minimally Invasive Percutaneous Nephrolithotomy with a Patented System Is Effective to Treat Renal Staghorn Calculi: A Prospective Multicenter Study[J]. Urol Int, 2018,101(2):143-149.

[39] Lievore E, Zanetti S P, Fulgheri I, et al. Cost analysis between mini-percutaneous nephrolithotomy with and without vacuum-assisted access sheath[J]. World J Urol, 2022,40(1):201-211.

[40] Zeng G H, Zhong W, Li X, et al. The Influence of Minimally Invasive Percutaneous Nephrolithotomy on Renal Pelvic Pressure In Vivo[J]. Surgical Laparoscopy Endoscopy & Percutaneous Techniques, 2007,17(4). (Guohua Z, Wen Z, Xun L, et al. The Influence of Minimally Invasive Percutaneous Nephrolithotomy on Renal Pelvic Pressure In Vivo[J]. Surgical Laparoscopy Endoscopy & Percutaneous Techniques, 2007,17(4).)

[41] De Coninck V, Keller E X, Rodríguez-Monsalve M, et al. Systematic review of ureteral access sheaths: facts and myths[J]. BJU International, 2018,122(6):959-969.

[42] Zhang Z L, Liu X H, Luo H B, et al. Risk factors and treatment of urosepsis after PCNL[J]. International Journal of Urology and Nephrology, 2017(02):206-209.

[43] Zanetti S P, Lievore E, Fontana M, et al. Vacuum-assisted mini-percutaneous nephrolithotomy: a new perspective in fragments clearance and intrarenal pressure control[J]. World J Urol, 2021,39(6):1717-1723.

[44] Yang Z, Song L, Xie D, et al. The New Generation Mini-PCNL System - Monitoring and Controlling of Renal Pelvic Pressure by Suctioning Device for Efficient and Safe PCNL in Managing Renal Staghorn Calculi[J]. Urol Int, 2016,97(1):61-66.

[45] Rivera M, Viers B, Cockerill P, et al. Pre- and Postoperative Predictors of Infection-Related Complications in Patients Undergoing Percutaneous Nephrolithotomy[J]. J Endourol, 2016,30(9):982-986.

[46] Chen D, Jiang C, Liang X, et al. Early and rapid prediction of postoperative infections following percutaneous nephrolithotomy in patients with complex kidney stones[J]. BJU International, 2019,123(6):1041-1047.

[47] Olvera-Posada D, Ali S N, Dion M, et al. Natural History of Residual Fragments After Percutaneous Nephrolithotomy: Evaluation of Factors Related to Clinical Events and Intervention[J]. Urology, 2016,97:46-50.

[48] Xie F, Deng S, Fei K, et al. Nomogram to predict the risk of adverse outcomes in patients with residual stones following percutaneous nephrolithotomy[J]. Int Braz J Urol, 2023,49 (5): 599-607.

[49] Degirmenci T, Bozkurt I H, Celik S, et al. Does leaving residual fragments after percutaneous nephrolithotomy in patients with positive stone culture and/or renal pelvic urine culture increase the risk of infectious complications?[J]. Urolithiasis, 2019,47 (4): 371-375.

[50] Rashid A O, Fakhulddin S S. Risk factors for fever and sepsis after percutaneous nephrolithotomy[J]. Asian journal of urology, 2016,3(2):82-87.

[51] Bonkat G, Cai T, Veeratterapillay R, et al. Management of Urosepsis in 2018[J]. European Urology Focus, 2019,5(1):5-9.

[52] Armstrong B A, Betzold R D, May A K. Sepsis and Septic Shock Strategies[J]. Surg Clin North Am, 2017,97(6):1339-1379.

[53] Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock[J]. N Engl J Med, 2001,345(19):1368-1377.

[54] Mouncey P R, Osborn T M, Power G S, et al. Trial of early, goal-directed resuscitation for septic shock[J]. N Engl J Med, 2015,372(14):1301-1311.

[55] Yealy D M, Kellum J A, Huang D T, et al. A randomized trial of protocol-based care for early septic shock[J]. N Engl J Med, 2014,370(18):1683-1693.

[56] Peake S L, Delaney A, Bailey M, et al. Goal-directed resuscitation for patients with early septic shock[J]. N Engl J Med, 2014,371(16):1496-1506.

[57] Mitchell K H, Carlbom D, Caldwell E, et al. Volume Overload: Prevalence, Risk Factors, and Functional Outcome in Survivors of Septic Shock[J]. Ann Am Thorac Soc, 2015,12(12):1837-1844.

[58] Hammond D A, Lam S W, Rech M A, et al. Balanced Crystalloids Versus Saline in Critically Ill Adults: A Systematic Review and Meta-analysis[J]. Ann Pharmacother, 2020,54(1):5-13.

[59] Semler M W, Self W H, Wanderer J P, et al. Balanced Crystalloids versus Saline in Critically Ill Adults[J]. N Engl J Med, 2018,378(9):829-839.

[60] Kumar A, Roberts D, Wood K E, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock[J]. Crit Care Med, 2006,34(6):1589-1596.

[61] Hu X, Yang Z Y, Hu H F, et al. Analysis of differences in distribution of pathogenic bacteria in urinary tract infection among different populations[J]. Chinese Journal of Primary Medicine and Pharmacy, 2023(12):1804-1807.

[62] Sun S H, Zhang J Y, Zeng L. Analysis of pathogenic bacteria culture and drug sensitivity test results in patients with urinary tract infection[J]. Chinese Journal of Practical Medicine, 2022(04):24-27.

[63] Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock[J]. N Engl J Med, 2018,378(9):797-808.

[64] Annane D, Bellissant E, Bollaert P E, et al. Corticosteroids for treating sepsis[J]. Cochrane Database Syst Rev, 2015,2015(12): CD002243.

[65] Rhodes A, Evans L E, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Intensive Care Med, 2017, 43 (3):304-377.

[66] Zhu Y, Yin H, Zhang R, et al. The effect of dobutamine in sepsis: a propensity score matched analysis[J]. BMC Infect Dis, 2021,21(1):1151.